Doyle Thomas James's Form 4 filing
Kura Oncology, Inc. (KURA) · filed Jan 31, 2024
- Accession no.
- 0000950170-24-009496
- Filed
- Jan 31, 2024
- Trade date
- Jan 29, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $41.3K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Doyle Thomas JamesCIK 0001910331 | Officer (SVP, Finance & Accounting) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 29, 2024 | Common Stock | SSaleDisposed | −594 | $17.80 | −$10,573.2 | 49,817 | Direct | |
| Jan 29, 2024 | Common Stock | SSaleDisposed | −761 | $17.80 | −$13,545.8 | 49,056 | Direct | |
| Jan 29, 2024 | Common Stock | SSaleDisposed | −963 | $17.80 | −$17,141.4 | 48,093 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.